Biohaven Pharmaceuticals
Ms. Frost has over 20 years of drug development experience with 18 years in various roles within Regulatory Affairs. She joined Biohaven after 11 years at Bristol-Myers Squibb, 5 years at CuraGen Corporation, and 5 years at Wyeth working in the therapeutic areas of neuroscience, virology, immunology, oncology and women’s health. Her experience spans all phases of drug development from preclinical research through Phases 3 and marketed products. Her numerous successful health authority interactions globally include approval of a new drug application for Daklinza and several Abilify sNDAs in the U.S. Ms. Frost has a B.A. in psychology from Northeastern University and a M.A. in behavioral neuroscience from the University of Connecticut.
This person is not in any offices
Biohaven Pharmaceuticals
6 followers
Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system.